Tomas Maira-Litran

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A
    Tomas Maira-Litran
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 7:e43813. 2012
  2. ncbi Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide
    Tomas Maira-Litran
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Infect Immun 70:4433-40. 2002
  3. ncbi Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine
    Tomas Maira-Litran
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Infect Immun 73:6752-62. 2005
  4. ncbi Poly-N-acetyl-β-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections
    Leticia V Bentancor
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Infect Immun 80:651-6. 2012
  5. ncbi Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections
    Leticia V Bentancor
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Infect Immun 80:3381-8. 2012
  6. ncbi Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice
    Victoria L Campodónico
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Infect Immun 79:3455-64. 2011
  7. ncbi Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection
    Andrea Kropec
    Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    Infect Immun 73:6868-76. 2005
  8. ncbi Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice
    David Skurnik
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Invest 120:3220-33. 2010
  9. ncbi Identification of Ata, a multifunctional trimeric autotransporter of Acinetobacter baumannii
    Leticia V Bentancor
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Bacteriol 194:3950-60. 2012
  10. ncbi Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide
    Tomas Maira-Litran
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, 181 Longwood Avenue, Boston, MA 02115, USA
    Vaccine 22:872-9. 2004

Collaborators

Detail Information

Publications15

  1. ncbi Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A
    Tomas Maira-Litran
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 7:e43813. 2012
    ..In conclusion, ClfA is an immunogenic carrier protein that elicited anti-adhesive antibodies that fail to augment the OPK and protective activities of antibodies to the PNAG cell surface polysaccharide...
  2. ncbi Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide
    Tomas Maira-Litran
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Infect Immun 70:4433-40. 2002
    ..These results further clarify the chemical structure of PS/A and help to differentiate it from PIA on the basis of immunogenicity, molecular size, and solubility...
  3. ncbi Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine
    Tomas Maira-Litran
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Infect Immun 73:6752-62. 2005
    ..aureus infection, including capsular polysaccharide types 5 and 8 and an untypable strain...
  4. ncbi Poly-N-acetyl-β-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections
    Leticia V Bentancor
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Infect Immun 80:651-6. 2012
    ..This was true for all four A. baumannii strains tested. Overall, these results highlight the potential of PNAG as a vaccine component for active immunization or as a target for passive antibody immunotherapy...
  5. ncbi Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections
    Leticia V Bentancor
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Infect Immun 80:3381-8. 2012
    ..The ability of Ata to engender anti-adhesive, bactericidal, opsonophagocytic, and protective antibodies validates its potential use as an antigenic target against MDR A. baumannii infections...
  6. ncbi Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice
    Victoria L Campodónico
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Infect Immun 79:3455-64. 2011
    ..Conjugation of PMA to FLA appears to be a promising path for developing a broadly protective vaccine against P. aeruginosa...
  7. ncbi Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection
    Andrea Kropec
    Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    Infect Immun 73:6868-76. 2005
    ..Thus, PNAG confers on S. aureus resistance to killing mediated by these innate host immune mediators. Overall, PNAG production by S. aureus appears to be a critical virulence factor as assessed in murine models of systemic infection...
  8. ncbi Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice
    David Skurnik
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Invest 120:3220-33. 2010
    ..aureus infections in humans could be due, in part, to interference in OPK when antibodies to CP and PNAG antigens are both present. This information could be used to better design S. aureus vaccine components...
  9. ncbi Identification of Ata, a multifunctional trimeric autotransporter of Acinetobacter baumannii
    Leticia V Bentancor
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Bacteriol 194:3950-60. 2012
    ..baumannii cells to collagen type IV, and contributing to the survival of A. baumannii in a mouse model of lethal infection...
  10. ncbi Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide
    Tomas Maira-Litran
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, 181 Longwood Avenue, Boston, MA 02115, USA
    Vaccine 22:872-9. 2004
    ..Animal studies have shown purified PNAG can elicit protective immunity against both CoNS and S. aureus, suggesting its potential as a broadly protective vaccine for many clinically important strains of staphylococci...
  11. ncbi Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine
    Nuno Cerca
    Channing Laboratory, Brigham and Women s Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Infect Immun 75:3406-13. 2007
    ..Retention of dPNAG on the surface of S. aureus is key to increased survival during bacteremia and also provides a molecular mechanism explaining the superior opsonic and protective activity of antibody to dPNAG...
  12. ncbi The pgaABCD locus of Acinetobacter baumannii encodes the production of poly-beta-1-6-N-acetylglucosamine, which is critical for biofilm formation
    Alexis H K Choi
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Bacteriol 191:5953-63. 2009
    ..Biofilm-dependent production of PNAG could be an important virulence factor for this emerging pathogen that has few known virulence factors...
  13. ncbi Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection
    David Skurnik
    Channing Laboratory, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Infect Dis 205:1709-18. 2012
    ....
  14. ncbi Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines
    Victoria L Campodónico
    Channing Laboratory, 181 Longwood Ave, Boston, MA 02115, USA
    Infect Immun 78:746-55. 2010
    ..aeruginosa based on flagellar antigens may require additional components beyond type a and type b proteins from prototype strains...
  15. ncbi Protection against Escherichia coli infection by antibody to the Staphylococcus aureus poly-N-acetylglucosamine surface polysaccharide
    Nuno Cerca
    Channing Laboratory, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 104:7528-33. 2007
    ..coli strains expressing PNAG. PNAG expression by both Gram-negative and Gram-positive organisms could make this antigen a conserved vaccine target for multiple pathogenic species of bacteria...